What happened with PRLD today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Prelude Therapeutics Incorporated discovers and develops medicines aimed at specific molecular targets involved in cancer. It remains a development-stage company: none of its products is approved for sale, and it has never generated revenue from selling medicines.
Partner agreements supply its revenue, with AbCellera providing most and Incyte the remainder. AbCellera pays upfront to license Prelude’s drug-development technology for selected antibody-based treatments. It controls the newly licensed programs worldwide and pays their development costs; Prelude can receive further payments when milestones are met and royalties if products reach the market. A separate joint-development collaboration with AbCellera remains in place.
Incyte has paid for an exclusive option to acquire Prelude’s JAK2 V617F program and associated assets. Prelude still owns and advances the program while the option is outstanding. If Incyte exercises the option and completes the purchase, Prelude could receive acquisition payments, further clinical and regulatory milestone payments, and royalties on future sales; otherwise, Prelude retains the assets.
The business depends on advancing candidates through trials and obtaining regulatory approval before medicines can be sold. Prelude relies on outside manufacturers and clinical-trial providers, and needs additional funding to continue development.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Incyte both funds Prelude and competes with its JAK2 V617F drug program: it paid $35 million for the exclusive right to buy the program for $100 million, while developing competing therapies and selling JAKAFI in the United States. Watch whether it exercises that right and closes the purchase; otherwise Prelude keeps ownership and responsibility for development.
AbCellera Biologics pays to use Prelude’s protein-degrading payloads and leads manufacturing for their original joint antibody-conjugate programs, while Prelude leads clinical development and commercialization. For the newly licensed programs, AbCellera controls development and pays all costs; their progress could bring Prelude milestone payments and single-digit royalties on future product sales.
Olema Pharmaceuticals’ OP-3136, which inhibits KAT6, competes with Prelude’s KAT6A-degrading drug program in breast cancer and other cancers. Olema has no approved products or product-sales revenue, so OP-3136’s clinical progress is the relevant signal for Prelude rather than sales.
Cogent Biosciences’ JAK2 research competes with Prelude’s JAK2 V617F inhibitor program. Cogent’s business centers on bezuclastinib, but its JAK2 program was still preclinical in 2025; watch that program’s progress for the direct competitive signal to Prelude.
IDEAYA Biosciences’ KAT6A development efforts directly compete with Prelude’s KAT6A-degrading drug program in precision cancer treatment. Its KAT6A development news is the part to follow for Prelude, rather than its separate darovasertib licensing income.
Pfizer’s KAT6A development efforts compete with Prelude’s KAT6A-degrading drug program for future use in cancer treatment. Pfizer earns most of its revenue by making and selling medicines; its KAT6A progress, rather than broad drug sales, is the news most directly relevant to this Prelude program.
Damora Therapeutics’ mutant-calreticulin therapies compete with Prelude’s antibody-linked CDK9 degrader for myeloproliferative neoplasms driven by mutant calreticulin. Watch its lead candidate DMR-001: Damora planned to apply to begin clinical trials in mid-2026.
BeOne Medicines’ KAT6A development efforts compete with Prelude’s KAT6A-degrading drug program. BeOne already sells cancer medicines, led by BRUKINSA for B-cell malignancies, but its KAT6A development news is the direct signal for Prelude’s competing program.
Incyte Genomics Inc earningsINCY
Incyte’s report may show whether it is moving ahead with buying Prelude’s JAK2 V617F program, which would shift development responsibility and could bring Prelude milestone payments.
Look for whether Incyte says it exercised its option and completed the purchase. If it did, Incyte takes responsibility for further development and Prelude may receive additional milestone payments; if not, Prelude retains the program and its development responsibility.
Prelude Therapeutics Incorporated earningsThis company
Prelude has no medicines for sale, so this report shows whether partner payments are keeping pace with the cash it spends developing drug candidates.
Read collaboration and license revenue alongside cash used in operations. More revenue with lower cash use would mean partner payments are doing more to support research and extend Prelude’s funding runway; less revenue or higher cash use would mean advancing its drug programs still depends on additional outside capital.
